Qu Qian, He Ye, Guo Zhi, Sun Yang, Fan Zhe-Xiang, Yi Yan-Hua, Zhu De-Cong, Hu Zhi-Qi, Miao Yong
From the Department of Plastic and Aesthetic Surgery, Nan Fang Hospital of Southern Medical University.
Department of Burn, Would Repair Surgery and Plastic Surgery, Department of Aesthetic Surgery, Affiliated Hospital of Guilin Medical University.
Plast Reconstr Surg. 2023 Apr 1;151(4):630e-640e. doi: 10.1097/PRS.0000000000010000. Epub 2022 Dec 6.
Studies have identified platelet-rich plasma (PRP) as a novel adjuvant therapy in androgenetic alopecia (AGA). However, the efficacy of PRP still needs to be improved. The purpose of this study was to assess the efficacy of PRP plus basic fibroblast growth factor (PRPF) for the treatment of AGA.
This was a prospective randomized, double-blind, placebo-controlled, half-head study. Eighty patients whose AGA was staged Norwood-Hamilton stages III to VII or Ludwig stages I to III were enrolled in the study from February of 2019 to September of 2019. Patients were divided randomly into two groups of 40 patients each and were given the following treatment: group 1, PRPF was injected in the right half and the left half with placebo; group 2, PRPF was injected in the right half and the left half with PRP. The treatment was processed three times, 1 month apart. Hair growth parameters were evaluated by trichoscope monthly until the sixth month of the study. Patient satisfaction, hair pull test, and side effects were recorded during follow-up.
Of the 80 patients included in the study, 47 were men and 33 were women with a mean age of 28.96 ± 4.82 years (range, 21 to 46 years). Both PRP and PRPF showed positive improvement ( P < 0.05) on hair count, terminal hair, and anagen hair after the treatment. Efficacy of PRPF revealed a significant improvement ( P < 0.05) in hair count, terminal hair, vellus hair, and anagen hair versus PRP. There was no statistical difference among any of the parameters in the placebo group.
PRPF can be a safe and valuable form of AGA treatment, and has proven to be more effective than PRP.
Hybrid therapy of PRP with relative growth factors, such as basic fibroblast growth factor, have prominent efficacy on treatment of AGA.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
研究已确定富血小板血浆（PRP）是雄激素性脱发（AGA）的一种新型辅助治疗方法。然而，PRP的疗效仍有待提高。本研究的目的是评估PRP联合碱性成纤维细胞生长因子（PRPF）治疗AGA的疗效。
这是一项前瞻性随机、双盲、安慰剂对照的半头部研究。2019年2月至2019年9月，纳入80例AGA处于诺伍德-汉密尔顿Ⅲ至Ⅶ期或路德维希Ⅰ至Ⅲ期的患者。患者被随机分为两组，每组40例，接受以下治疗：第1组，右半侧注射PRPF，左半侧注射安慰剂；第2组，右半侧注射PRPF，左半侧注射PRP。治疗进行3次，间隔1个月。每月用毛发镜评估头发生长参数，直至研究的第6个月。随访期间记录患者满意度、拔毛试验和副作用。
本研究纳入的80例患者中，男性47例，女性33例，平均年龄28.96±4.82岁（范围21至46岁）。治疗后，PRP和PRPF在毛发数量、终毛和生长期毛发方面均显示出阳性改善（P<0.05）。与PRP相比，PRPF在毛发数量、终毛、毳毛和生长期毛发方面的疗效有显著改善（P<0.05）。安慰剂组各参数之间无统计学差异。
PRPF可能是一种安全且有价值的AGA治疗方式，且已证明比PRP更有效。
PRP与相对生长因子（如碱性成纤维细胞生长因子）的联合治疗对AGA治疗具有显著疗效。
临床问题/证据水平：治疗性，Ⅱ级。
